CHICAGO — GLP-1, or Glucagon-like peptide-1, medications, similar to Ozemppic and Wegovy, are becoming more accessible, and ...

Corxel Pharmaceuticals (CORXEL), a leading biotech company committed to bringing innovative science and medicines to underserved patients with cardiometabolic diseases around the world, today ...

The molecule contains GLP-1, glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. It was administered ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

Glucagon-like peptide 1 receptor agonists ... combine the beneficial effects of two or more hormones into a single molecule — are being explored, with a dual GLP-1R/ gastric inhibitory ...

NDAQ:VKTX) Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity ...

Glucagon is a natural hormone that counterbalances ... There is also competition from new small molecule and oral obesity drugs, which are showing strong clinical data for possible use in both ...

Structure Therapeutics Inc. has selected a lead oral small-molecule amylin receptor agonist ... that is being evaluated for use either alone or in combination with glucagon-like peptide-1 (GLP-1) ...